Neuropeptides

Definition & General Overview

• Neuropeptides = chains of $(2+)$ amino acids (AAs) joined by peptide bonds.

• Most diverse class of central-nervous-system (CNS) signaling molecules ( $>$ $100$ bio-active species identified).

• Functional identities

  • Neurotransmitters: fast, point-to-point synaptic actions.

  • Neuromodulators: fine-tune excitability & transmitter release.

  • Neurohormones: endocrine-like, volume transmission via cerebrospinal fluid (CSF) or blood.

• Influence virtually every brain domain: transmitter release, firing patterns, emotion, motivation, cognition, autonomic & endocrine outputs.

Core Physiologic & Behavioral Roles

• Homeostasis

  • Thermoregulation

  • Food & water intake

  • Sleep–wake cycling & locomotion

• Information processing

  • Learning & memory consolidation

  • Attentional modulation

• Stress–pain axis

  • HPA activation, analgesia / hyperalgesia.

• Affect & social cognition

  • Anxiety, depression, reward, attachment, aggression.

• Clinical links: autism, schizophrenia, mood & anxiety disorders, PTSD.

Key Named Neuropeptides

• Hypothalamic releasing hormones

  • TRH → stimulates TSH.

  • CRF → stimulates ACTH.

• Neurohypophysial

  • Oxytocin (OT) → social bonding, uterine contraction, lactation.

  • Arginine-vasopressin (AVP) → antidiuresis, vascular tone, social behavior.

• Others

  • Neurotensin (NT) → dopaminergic modulation, analgesia.

  • Neuropeptide Y (NPY) → appetite, stress resilience.

  • Somatostatin, Galanin, Substance P, CCK, Orexins, etc.

Dual Central vs. Peripheral Actions

• OT & AVP

  • CNS: pair bonding, parental care, empathy.

  • Periphery: uterine contraction, milk ejection (OT); renal water retention (AVP).

• μ-opioid peptides / receptors

  • CNS: analgesia, reward.

  • Periphery: respiratory depression, constipation.

• Coordinated maternal behavior recruits both OT & AVP systems.

Biosynthesis Pipeline

1. Gene transcription → precursor mRNA.

2. Translation in rough ER → preprohormone (contains signal peptide, SP).

3. Signal peptide cleavage → prohormone.

4. Golgi packaging into dense-core granules.

5. Proteolytic processing by prohormone convertases (PC $1/3$, PC $2$) at dibasic motifs (e.g., Lys-Arg).

6. Exoproteolysis by carboxy- & aminopeptidases → mature peptide(s).

• Single preprohormone can yield multiple distinct peptides (e.g., POMC → ACTH, β-endorphin).

Gene Architecture & Regulation

• Usually multi-exon; SP encoded in 5′ region.

• Promoters controlled by cell-specific transcription factors (e.g., CREB, steroid receptors).

• Viral-vector experiments define OT gene enhancers.

Post-Translational Modifications

• Amidation (C-terminal $− ext{CONH}_2$) ↑ stability/receptor affinity (e.g., TRH).

• Cyclization → pyroglutamate at N-terminus (TRH).

• Disulfide bonding (OT, AVP) confers cyclic structure.

• Glycosylation / phosphorylation tune trafficking.

• Alternative RNA splicing: calcitonin vs. CGRP isoforms.

CNS Distribution

• Not restricted to classic endocrine sites; dense-core vesicle neurons exist in:

  • Hypothalamus (portal regulation).

  • Limbic system (emotion).

  • Cortex (cognition).

  • Midbrain/hindbrain (motor, autonomics).

  • Spinal cord (pain gating).

Co-Transmission Paradigm

• Peptides coexist with small-molecule transmitters in single terminals.

  • First report: Somatostatin + GABA ( $1977$ ).

  • NPY & Galanin with norepinephrine (NE) in locus coeruleus/adrenal medulla.

• Release hierarchy: high-frequency or burst firing → peptide exocytosis (DCVs) alongside classical vesicles.

• Volume transmission: extrasynaptic diffusion to distant GPCRs.

• Glia can also secrete peptides.

Receptor Landscape

• Majority are GPCRs; couple to:

  • $G_s$ → ↑ adenylate cyclase, $↑$ $cAMP$.

  • $G_i/o$ → ↓ adenylate cyclase, open $K^+$, close $Ca^{2+}$.

  • $G<em>q/11$ → PLCβ → $IP</em>3$ + DAG → $Ca^{2+}$ mobilization, PKC.

• Homo- & hetero-dimerization expands signaling repertoire.

• Multiple subtypes per ligand (e.g., AVP: V$1a$, V$1b$, V$2$).

• Cross-reactivity: OT can activate AVP receptors and vice-versa.

• Species-specific expression (vole studies) underlies social diversity.

Degradation & Termination

• No reuptake transporters; signal ends via peptidases.

• Half-life: minutes.

• Enzyme classes

  • Serine endopeptidases (trypsin).

  • Thiol peptidases (cathepsins).

  • Acid proteases (pepsin, renin).

  • Metalloendopeptidases: neprilysin, ACE.

  • Metalloexopeptidases: amino- & carboxypeptidases.

• Peptidases play dual roles: processing vs. degradation (e.g., Carboxypeptidase B).

• Pharmacology: selective inhibitors scarce; ACE inhibitor class is successful prototype.

Drug-Discovery Principles for Peptide Systems

• Challenge: native peptides $\not$ BBB-permeable.

• Strategies

  • Engineer brain-penetrant analogs (mixed success).

  • Develop <$(500)$-Da small molecules for GPCRs.

  • Agonist / antagonist / inverse agonist.

  • PAMs & NAMs (allosteric).

  • Biased agonism → pathway-selective therapeutic windows.

  • Gene therapy / CRISPR, RNAi, Cre-Lox for circuit dissection.

  • Opto- & chemogenetics for temporally precise activation.

  • PET ligands to image receptor occupancy in humans.

Thyrotropin-Releasing Hormone (TRH)

• First hypothalamic releasing factor ( $1969$ ).

• HPT axis: TRH (PVN) → portal blood → TSH → thyroid → $T<em>3$/$T</em>4$; negative feedback on TRH & TSH gene expression.

• Cold exposure can override feedback (thermogenic drive).

• Extra-hypothalamic TRH neurons (olfactory bulb, hippocampus, amygdala, midbrain) unaffected by thyroid hormones; modulate DA, 5-HT, ACh, opioids.

• Psychiatry

  • $25\%$ euthyroid depressed pts: blunted TSH response to exogenous TRH.

  • CSF TRH ↑ in depression, yet PVN TRH mRNA ↓ (suggests hypersecretion/adaptation).

  • High basal TSH ($>$ $3.5$ $\text{mIU/mL}$) ⇒ poorer antidepressant response.

Corticotropin-Releasing Factor (CRF) & Urocortins

• CRF gene: chromosome $8q13$ (exon $2$ encodes peptide).

• Urocortin $1,2,3$ = paralogs with similar architecture.

• Paraventricular CRF neurons drive ACTH → cortisol.

• Regulation

  • Glucocorticoids ↓ CRF mRNA in PVN but may ↑ in amygdala.

  • Stressors & adrenalectomy ↑ CRF expression.

• Psychopathology

  • Depression/PTSD: hypercortisolemia, elevated CSF CRF, blunted ACTH to CRF.

  • Early trauma: ↑ CRF in locus coeruleus (LC) → heightened arousal.

  • Serotonin (raphe) & NE (LC) modulation → anxiety, anhedonia.

Oxytocin (OT) & Vasopressin (AVP)

• Cyclic nonapeptides; differ by $2$ AAs.

• Genes on chromosome $20p13$, opposite orientation; derived from ancestral duplication.

• Synthesized in PVN & SON; axonal release into bloodstream + dendritic/CNS release.

• Peripheral

  • OT: labor, milk let-down, sexual climax.

  • AVP: renal V$2$ receptor → water reabsorption; V$1a$ vascular tone.

• Central social circuitry

  • OT: empathy, trust, maternal care, striatal reward, auditory gating of pup calls.

  • AVP: territoriality, aggression, male pair-bonding; stronger in males.

• Clinical

  • Anxiety: OT dampens amygdala; AVP can potentiate CRF anxiogenesis.

  • Autism: CSF OT & AVP ↓; intranasal OT/AVP improves social metrics.

  • Aggression/psychopathy: CSF AVP ↑; OT improves emotion recognition.

• Therapeutics

  • Intranasal peptides show acute prosocial effects but BBB permeability limited.

  • Alternative: small-molecule OT enhancers, melanocortin agonists, MDMA-evoked OT surge.

  • Precision medicine: receptor SNP profiling.

Neurotensin (NT)

• Discovered $1973$ (hypotensive activity).

• Gene on chromosome $12q21$; precursor encodes NT + neuromedin N.

• Distribution: VTA, SNc, ventral striatum, extended amygdala, lateral septum, arcuate nucleus; co-localized with dopamine (DA).

• Receptors

  • NTR$1$ & NTR$2$ = GPCRs; NTR$3$ = sortilin-like single TM.

  • NTR$1$ primarily modulates DA.

• Schizophrenia links

  • NT inhibits DA-stimulated locomotion, enhances prepulse inhibition (sensorimotor gating).

  • Antipsychotics ↑ NT levels → NT may mediate therapeutic effects.

• Drug development: BBB-penetrant NTR$1$ agonists sought; peptide rapidly degraded.

Other Psychiatric-Relevant Peptides

• Cholecystokinin (CCK)

  • CCK$1$ (gut) vs. CCK$2$ (brain).

  • IV CCK can provoke panic; heightened CCK sensitivity & receptor polymorphisms in panic disorder.

• Substance P (SP)

  • Expressed in amygdala, hypothalamus, LC, PAG; pain & stress mediator.

  • CSF SP ↑ in PTSD & MDD.

  • NK$1$ antagonists failed in depression trials but effective anti-emetics (aprepitant).

• Neuropeptide Y (NPY)

  • Hypothalamus, brainstem, limbic.

  • High NPY = resilience; low NPY = PTSD/depression vulnerability.

  • Y$2$ receptor antagonists under preclinical evaluation.

• Galanin

  • Interacts with NE & 5-HT; GalR$3$ overactivity in LC linked to depression/suicide.

  • Genetic variants ↑ risk; GalR$3$ antagonist SNAP$37889$ toxic.

• Orexins (Hypocretins)

  • Orexin A/B sustain wakefulness; deficiency → narcolepsy (autoimmune loss).

  • Dual orexin receptor antagonists (suvorexant, lemborexant) approved for insomnia.

  • Exploratory roles in addiction & obesity.

Ethical, Philosophical & Practical Considerations

• Manipulating social peptides (OT/AVP) raises questions about consent, authenticity of emotion, potential misuse in advertising or interrogation.

• Gene-editing or chemogenetic modulation of neuropeptide circuits necessitates rigorous oversight (off-target, developmental effects).

• Translational gap: rodent social paradigms ↔ human complex behaviors; species receptor distribution differs.

Integrative Take-Home Points

• Neuropeptides add a slow, diffuse, state-setting layer atop fast synaptic networks.

• Single genes → multiple peptides → pleiotropic actions; conversely, single peptide → multiple receptor subtypes → diverse signaling.

• Dysregulation at any level (gene, processing, release, receptor, degradation) can manifest as psychiatric or neurologic disease.

• Therapeutic success hinges on brain penetration, receptor subtype selectivity, and signaling bias to maximize benefit & minimize side-effects.

• Emerging technologies (CRISPR, PET, optogenetics, allosteric drugs) are rapidly expanding our capacity to map & modulate neuropeptide systems for precision psychiatry.